Stockscreener 앱 받기
0.7702
3.73%
-0.0298
시간 외 거래:
.79
0.0198
+2.57%
Fibrobiologics Inc 주식(FBLG)의 최신 뉴스
Fibrobiologics Inc (FBLG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fibrobiologics Inc (FBLG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fibrobiologics Inc (FBLG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FibroBiologics (FBLG) Initiates Dosing in Clinical Trial for Dia - GuruFocus
FibroBiologics doses first patients in diabetic foot ulcer trial By Investing.com - Investing.com Nigeria
FibroBiologics Doses First Patients in Phase 1/2 Trial of CYWC628 for Diabetic Foot Ulcers - Moomoo
FibroBiologics doses first patients in diabetic foot ulcer trial - Investing.com UK
FibroBiologics Initiates First Patient Dosing in Phase 1/2 Clinical Trial for CYWC628 in Diabetic Foot Ulcers - Quiver Quantitative
First patients get FibroBiologics' CYWC628 for chronic diabetic foot ulcers - Stock Titan
FBLG Q1 2026 Earnings: Slight EPS Miss as Pre-Revenue Biotech Advances PipelineHigh Estimate Range - newsline.com
FibroBiologics (FBLG) Declines Amid Volatility, Nears Critical Support ZoneValue Area Low - newsline.com
FibroBiologics Inc. (FBLG) Slides 3% as Selling Pressure Tests Key Support ZoneEnding Diagonal - newsline.com
FIBROBIOLOGICS INC (FBLG) Stock Chart - ChartMill
FibroBiologics Inc. (FBLG) Q1 2026 Earnings: Narrow EPS Miss Highlights Pre-Revenue Biotech Challenges - newsline.com
FBLG: Phase 1/2 Trial of CYWC628 Underway - Zacks Small Cap Research
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - Sahm
FibroBiologics begins dosing patients in diabetic ulcer trial By Investing.com - Investing.com South Africa
FibroBiologics begins dosing patients in diabetic ulcer trial - Investing.com UK
FibroBiologics (FBLG) Begins Clinical Trial for Diabetic Foot Ulcers Treatment - GuruFocus
Fibrobiologics Announces First Patients Dosed In Phase 1/2 Clinical Trial Evaluating Cywc628 For The Treatment Of Diabetic Foot Ulcers - TradingView
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - The Manila Times
Experimental cell therapy for diabetic foot ulcers starts dosing patients - Stock Titan
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data? - Insider Monkey
10 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
FBLG Stock Price, Quote & Chart | FIBROBIOLOGICS INC (NASDAQ:FBLG) - ChartMill
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - Sahm
D. Boral Capital Maintains FibroBiologics (FBLG) Buy Recommendation - MSN
symbol__ Stock Quote Price and Forecast - CNN
FibroBiologics Presents Preclinical Data Demonstrating - GlobeNewswire
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics files patent for oral fibroblast delivery system - Investing.com UK
FibroBiologics files patent for oral fibroblast delivery system By Investing.com - Investing.com Australia
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - GlobeNewswire
Exclusive: FibroBiologics targets 2026 data readout after trial progress for diabetic foot ulcer study - MSN
TradingKey - TradingKey
Fibrobiologics explores use of fibroblast platform for hantavirus - BioWorld News
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - GlobeNewswire
Severe Hantavirus syndrome lacks drugs, FibroBiologics tests fibroblast therapy - Stock Titan
FibroBiologics, Inc. Files Form 8-K Announcing Material Definitive Agreement and Company Details - Minichart
0.74%
1.44%
자본화:
|
볼륨(24시간):